LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) announced it has been added to the Russell Microcap(R) Index, effective after the close of U.S. markets on June 26, 2026, with the reconstituted index taking effect at the opening of trading on June 29, 2026. The inclusion in this widely followed benchmark is expected to increase the company's visibility among institutional investors and investment products that track Russell indexes, according to the company.
The milestone reflects progress under LIXTE's new leadership and strategic direction, supporting its efforts to build a platform focused on AI energy infrastructure equipment and services. The Russell Microcap Index is reconstituted annually and measures the performance of smaller publicly traded U.S. companies. For more details, the full press release is available at https://ibn.fm/r6l81.
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical and med-tech company with a dual focus: cancer drug development and advanced proton therapy systems. Through its wholly owned subsidiary, Liora Technologies Europe Ltd., LIXTE is pioneering electronically controlled proton therapy systems for treating tumors. Its proprietary LiGHT System is believed to offer significant advantages over current technologies. Additional information about Liora Technologies can be found at www.lioratechnologies.com.
In the pharmaceutical arena, LIXTE's lead compound, LB-100, is a first-in-class clinical PP2A inhibitor that has shown tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to enhance chemotherapies and immunotherapies, improving outcomes for patients. The company is advancing an entirely new field of cancer biology—activation lethality—supported by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma.
This index inclusion marks a significant step for LIXTE as it navigates a strategic transformation. By joining the Russell Microcap Index, the company gains exposure to a broader investor base, which could facilitate capital raising and partnerships. For investors and the industry, this move signals LIXTE's commitment to expanding beyond its oncology roots into the AI energy infrastructure sector, potentially opening new revenue streams. The increased visibility may also attract analyst coverage and institutional interest, driving liquidity and valuation. As the company executes on its dual strategy, the coming months will be critical to watch for clinical trial updates and progress in the AI energy space.
